Product Description
Dong-A was developing da-5202, and injectable drug, for the treatment of osteoarthritis of the knee (Sourced from https://clinicaltrials.gov/ct2/show/NCT02554240)
Mechanisms of Action: Unknown
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Dong-A
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Osteoarthritis, Knee
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02554240 |
DA5202_KOA_II | P2 |
Completed |
Osteoarthritis, Knee |
2016-06-29 |
2021-04-15 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|